“Our aim is to make impactful discoveries that will change patient lives”  
T. Baumert

By harnessing our unique knowledge and several multidisciplinary competencies, and by taking advantage of cutting-edge technologies and models in our state-of-the-art facilities we are spearheading liver disease research with our flagship innovative programs addressing the next challenges.

Our key objectives:

  • Unravel the cell circuits driving liver disease progression
  • Develop innovative patient-derived models for liver disease
  • Uncover SARS-CoV-2 / HBV / HCV / HDV hepatocytes interactions
  • Translate discoveries into novel therapeutic strategies


The Institute is proud to be a laureate of the prestigious award Laboratory of Excellence (LabEx), since 2011 as part of the French national program “Investments for the Future” and more recently the “Initiative of excellence” (IDEX) of the University of Strasbourg.

We are part of the Scientific Excellence Cluster Integrative Molecular and Cellular Biology (ITI IMCBio) of the University of Strasbourg together with the IGBMC, IBMC, IBMP, GMGM. This cluster unites the forces of four LabEx of complementary leading expertise in molecular and cellular biology, INRT (Integrative biology: Nuclear dynamics, Regenerative and Translational medicine), MitoCross (Mitochondria-nucleus Cross-talk), NetRNA (Networks of regulatory RNAs) and our very own HepSYS (Functional genomics of viral hepatitis and liver disease). This cluster drives scientific excellence and collaboration at the local level and also provides unique training opportunities for Master and PhD candidates in the frame of the Graduate School “Integrative Molecular and Cellular Biology” (EUR IMCBio).


Our team owns unique knowledge and skills, by employing cutting-edge technologies, state-of-the-art facilities and models,  and combining multidisciplinary competencies from cell biologists, virologists, and hepatologists. the urgent need for alternative strategies